Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Rhea-AI Summary

Enlivex (Nasdaq: ENLV) announced issuance of Australian patent 2020340629 covering methods of using Allocetra™ to treat osteoarthritis. The patent provides protection in Australia through at least 2040, expanding Allocetra’s osteoarthritis IP coverage as a Phase 2b knee osteoarthritis trial advances with the first U.S. patient dosed.

Positive

• Australian Allocetra™ osteoarthritis patent protection through at least 2040
• Additional major jurisdiction strengthens global Allocetra™ intellectual property position
• Phase 2b clinical trial active with first U.S. patient dosed
• Company previously reported positive three- and six-month topline Allocetra™ knee OA data

Negative

• None.

News Market Reaction – ENLV

-1.49%

5 alerts

-1.49% Session close to close

-11.3% Trough in 56 min

$159.12M Market Cap

0.2x Rel. Volume

In the Jun 15 session, ENLV declined 1.49%, reflecting a mild negative market reaction. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds an Australian patent, protecting Allocetra™ osteoarthritis use through at lea...

Analysis

This announcement adds an Australian patent, protecting Allocetra™ osteoarthritis use through at least 2040, as the program advances into a randomized, placebo-controlled Phase 2b trial. Recent history shows mixed price responses to positive clinical and treasury news, so investors may track upcoming Allocetra™ data and enrollment milestones. The existing Form F‑3 registering up to 23,333,333 shares for resale and Nasdaq minimum bid requirements are additional context points to monitor alongside clinical progress.

Key Figures

Australian patent number: 2020340629 Patent protection term: through at least 2040 Phase: Phase 2b +5 more

8 metrics

Australian patent number 2020340629 Patent covering Allocetra™ use in osteoarthritis

Patent protection term through at least 2040 Australian Allocetra™ osteoarthritis patent duration

Phase Phase 2b Clinical program for Allocetra™ in knee osteoarthritis

Trial design Phase I/II double-blind, randomized, placebo-controlled ENX-CL-05-001 knee osteoarthritis trial

Topline data timepoints 3-month and 6-month Positive topline results in Phase I/II ENX-CL-05-001

Price change -6.8% 24h move prior to/around patent news

52-week range $0.66–$2.10 52-week low and high for ENLV

Registered shares 23,333,333 shares Ordinary shares registered for resale under Form F-3

Historical Context

5 past events · Latest: Jun 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Conference sponsorship	Neutral	-1.6%	Gold sponsorship and longevity model presentation at Proof of Talk 2026.
Jun 01	Clinical data update	Positive	+6.5%	Phase IIa Allocetra data showed significant, durable pain and function improvement.
May 28	Treasury valuation update	Positive	-2.3%	RAIN token holdings valued near $1.16 billion with protocol growth metrics.
May 27	Treasury portfolio news	Positive	+14.3%	Rain protocol entered top three prediction markets after $100M liquidity.
May 18	Trial enrollment start	Positive	-3.2%	First U.S. patient dosed in global Phase 2b Allocetra knee OA trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often reads positively but price reactions are mixed, with several clinically or strategically positive updates followed by negative or muted moves.

Recent Company History

Over the last month, Enlivex has reported several milestones around Allocetra™ and its prediction markets-focused treasury. On May 18, 2026, it announced first U.S. dosing in a global Phase 2b OA trial, followed by Denmark CTA approval and extended efficacy data showing durable 3- and 6‑month benefits in knee OA on June 1, 2026. In parallel, multiple treasury updates highlighted large RAIN token holdings and added liquidity. Despite this, market reactions have alternated between gains and selloffs, indicating inconsistent alignment between news flow and price.

Key Terms

apoptotic cells, osteoarthritis, phase 2b, double-blind, +2 more

6 terms

apoptotic cells medical

"titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”."

Apoptotic cells are cells that are undergoing a controlled, programmed death process the body uses to remove damaged or unneeded cells without causing inflammation. Think of it as a tidy, planned demolition rather than an explosion. For investors, the presence or absence of apoptotic cells in lab tests or clinical trials signals how well a therapy hits its target and whether it may cause harmful side effects, affecting trial outcomes, regulatory decisions and commercial prospects.

osteoarthritis medical

"methods of using Allocetra™ to treat subjects with osteoarthritis."

A chronic joint condition in which the protective cushioning (cartilage) between bones gradually breaks down, causing pain, stiffness and reduced mobility—think of joints like shock absorbers that wear out over time. It matters to investors because it represents a large, predictable market for medicines, surgical devices and long‑term care; clinical trial results, regulatory decisions, reimbursement and new treatments can significantly affect sales, costs and valuation in healthcare-related companies.

phase 2b medical

"as the Phase 2b clinical program for Allocetra™ advances."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

double-blind medical

"two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

randomized medical

"two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

placebo-controlled medical

"two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this issuance, the Company has secured patent protection for Allocetra™ in osteoarthritis in an additional major jurisdiction, further strengthening its global intellectual property position as the Phase 2b clinical program for Allocetra™ advances.

Enlivex recently reported the dosing of the first patient at a U.S. clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The Phase 2b follows Enlivex’s previous announcement regarding positive three-month and six-month topline data from the Phase 2b stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial that evaluated Allocetra™ in patients with moderate-to-severe knee OA.

About Enlivex (Nasdaq: ENLV)

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

About Knee Osteoarthritis

Knee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com

FAQ

What patent did Enlivex (ENLV) receive in Australia for Allocetra™ and osteoarthritis?

Enlivex received Australian patent 2020340629 covering methods of using Allocetra™ to treat osteoarthritis. According to Enlivex, this patent extends intellectual property protection for Allocetra™ in Australia through at least 2040, adding a key jurisdiction to its osteoarthritis patent portfolio.

How long does the new Australian Allocetra™ patent protect Enlivex (ENLV) in osteoarthritis?

The Australian patent provides Enlivex protection for Allocetra™ in osteoarthritis through at least 2040. According to Enlivex, the patent’s claims cover methods of using Allocetra™ to treat osteoarthritis patients, supporting the company’s long-term intellectual property position in this indication.

How does the Australian Allocetra™ patent impact Enlivex’s (ENLV) global IP strategy?

The new Australian patent adds another major jurisdiction for Allocetra™ osteoarthritis protection. According to Enlivex, this issuance further strengthens its global intellectual property position for Allocetra™ as development in osteoarthritis continues, potentially supporting future partnering or commercialization discussions.

What is the status of Enlivex’s (ENLV) Phase 2b trial of Allocetra™ in knee osteoarthritis?

Enlivex has begun dosing patients in its Phase 2b Allocetra™ knee osteoarthritis trial, including the first U.S. site patient. According to Enlivex, the study targets moderate-to-severe age-related symptomatic primary knee osteoarthritis, building on prior Phase I/II data.

What prior clinical results has Enlivex (ENLV) reported for Allocetra™ in knee osteoarthritis?

Enlivex previously announced positive three-month and six-month topline data from ENX-CL-05-001. According to Enlivex, this was a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.

Why is the Australian osteoarthritis patent important for Enlivex (ENLV) shareholders?

The patent extends Allocetra™ osteoarthritis protection in a major market through at least 2040. According to Enlivex, securing this jurisdiction strengthens its global IP portfolio, which can be important for future commercialization, potential partnerships, and competitive positioning in osteoarthritis therapies.